Bristol Myers Squibb and Pfizer announced that 22 abstracts will be presented at the American Heart
Association (AHA) Scientific Sessions 2015, to be held November 7-11 in
Orlando, Florida. The new data, including four oral presentations,
contribute to the Bristol-Myers Squibb and Pfizer Alliance’s research in
nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE)
in patients treated with Eliquis. Abstracts include new data analyses from the pivotal Phase 3 study, ARISTOTLE, as well as a number of real-world data analyses.
Eliquis (apixaban) is an oral selective Factor Xa inhibitor. By inhibiting Factor Xa, a key blood clotting protein, Eliquisdecreases thrombin generation and blood clot formation. Eliquis is approved for multiple indications in the U.S. based on efficacy and safety data from seven Phase 3 clinical trials. Eliquis is a prescription medicine indicated
to reduce the risk of stroke and systemic embolism in patients with
nonvalvular atrial fibrillation (NVAF); for the prophylaxis of deep vein
thrombosis (DVT), which may lead to pulmonary embolism (PE), in
patients who have undergone hip or knee replacement surgery; for the
treatment of DVT and PE; and to reduce the risk of recurrent DVT and PE,
following initial therapy.
